CWWBF (Plant Based Investment) Debt-to-Equity: 0.00 (As of Jul. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Plant Based Investment Debt-to-Equity?

Plant Based Investment CWWBF -90.00% Debt-to-Equity is 0.00 as of Jul. 2022.

Plant Based Investment's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2022 was $0.00 Mil. Plant Based Investment's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2022 was $0.00 Mil. Plant Based Investment's Total Stockholders Equity for the quarter that ended in Jul. 2022 was $9.45 Mil. Plant Based Investment's debt to equity for the quarter that ended in Jul. 2022 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Plant Based Investment's Debt-to-Equity or its related term are showing as below:

CWWBF's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.28
* Ranked among companies with meaningful Debt-to-Equity only.

Plant Based Investment  (OTCPK:CWWBF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Plant Based Investment Debt-to-Equity Related Terms

Plant Based Investment Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Plant Based Investment's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Plant Based Investment Debt-to-Equity Chart

Plant Based Investment Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21
Debt-to-Equity
N/A 0.01 0.00 0.00 0.01

Plant Based Investment Quarterly Data
Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.02 0.01 0.00

CWWBF vs ZTS, CTLT, VTRS: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Plant Based Investment's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Plant Based Investment Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Plant Based Investment's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Plant Based Investment's Debt-to-Equity falls into.


Plant Based Investment Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Plant Based Investment's Debt to Equity Ratio for the fiscal year that ended in Oct. 2021 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0.084) / 18.123
=0.00

Plant Based Investment's Debt to Equity Ratio for the quarter that ended in Jul. 2022 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 9.446
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Plant Based Investment (CWWBF) has a Debt-to-Equity of 0.00 as of Jul. 2022. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Plant Based Investment and its competitors.
Is Plant Based Investment's Debt-to-Equity too high?
Plant Based Investment's current Debt-to-Equity is 0.00.
How does Plant Based Investment's Debt-to-Equity compare to ZTS and CTLT?
Plant Based Investment's Debt-to-Equity of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Plant Based Investment and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Plant Based Investment's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plant Based Investment stock overvalued right now?
Plant Based Investment (CWWBF) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Plant Based Investment (CWWBF), the current Debt-to-Equity is 0.00 as of Jul. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Plant Based Investment Business Description

Address 240 Richmond Street West, Suite 4164, Toronto, ON, CAN, M5V1V6
Plant Based Investment Corp is an investment corporation that seeks to provide shareholders long-term total returns through capital appreciation and periodic distributions by investing in an actively managed portfolio of securities in public and private companies that derive a portion of their revenues, earnings or intellectual property-based value from products, equipment, services and/or technologies related to plant-based industries, including the cannabis plant family and its various compounds, the fungi industry (including medicinal, functional and psychedelics), super-foods and/or organic ingredients industries in addition to investing in specialty retail locations, functional medicine and wellness-based clinics and treatment centers.